ALK still has two horses in adrenaline race
ALK has two cards up its sleeve in its efforts to take shares of the adrenaline market. However, its in-house developed pen and partner Windgap's product may end up running heats for a spot in the final, as CEO Carsten Hellmann says they will "probably choose one at some point."
by albert rønning-andersoon, translated by catherine brett
Allergy specialist firm ALK has still got two horses in the race to become the leading adrenaline pen distributor in the US.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Global supply issues have ALK thinking creatively
For subscribers
ALK upgrades guidance after positive Q3 report
For subscribers
